Adult male obesity prevalence in South Korea has surpassed 51%, according to the 2026 Obesity Fact Sheet published by the Korean Society for the Study of Obesity.

Rising Rates of Male Abdominal Obesity in South Korea

The Korean Society for the Study of Obesity reported that male abdominal obesity has reached 32.4% nationwide. Age-specific data indicates that the condition affects 32.4% of men aged 30 to 34, 38.4% of those aged 35 to 39, 38.3% of individuals aged 40 to 44, and 35.4% of adults aged 45 to 49. This persistent concentration of abdominal fat among men in their 30s and 40s has drawn attention from medical professionals who warn that standard weight measurements often fail to capture underlying metabolic risks.

Evaluating Body Composition Changes During Treatment

Modern clinical approaches to weight management emphasize the quality of weight loss over simple numerical drops on a scale. According to clinical findings from the SEMALEAN study involving 106 obesity patients, treatment with the GLP-1 receptor agonist semaglutide resulted in an average weight loss of 10% at seven months and 13% at 12 months. The study recorded that 59% of patients achieved a weight reduction of 10% or more, while 26% lost over 15% of their starting weight.

Crucially, body composition analyses using dual-energy X-ray absorptiometry revealed that total fat mass decreased by 18.9% at the 12-month mark, alongside significant reductions in visceral fat. Lean mass—which includes muscle, bone, and water—experienced an initial average drop of 3kg by month seven but remained stable thereafter through month 12. Consequently, the ratio of lean mass to total body weight actually increased. Handgrip strength, a standard proxy for muscle function, rose from an initial baseline average of 27.6kg to 4.1kg higher (+15%) after 12 months. Furthermore, the prevalence of sarcopenic obesity dropped from 49% prior to treatment down to 33% at the conclusion of the study.

Cardiovascular Risk Reduction Linked to Waist Circumference

Beyond body composition shifts, large-scale clinical trials have linked targeted abdominal fat reduction to measurable drops in cardiovascular events. The SELECT trial, which tracked overweight and obese patients with existing cardiovascular disease, found that participants receiving semaglutide experienced a 20% lower risk of major adverse cardiovascular events—such as cardiovascular death, non-fatal myocardial infarction, and stroke—compared to a placebo group.

Waist circumference measurements in the SELECT trial showed an average reduction of 7.7cm in the treatment group at 208 weeks, contrasted with a 1.3cm reduction in the control group. Subsequent analyses suggested that roughly 33% of the observed cardiovascular benefits were mediated directly by the reduction in waist circumference. Researchers noted that these findings connect localized abdominal fat loss to broader systemic cardiovascular protection.

Long-Term Goals for Metabolic Health

Medical experts emphasize that effective obesity care must target metabolic health rather than aesthetic goals alone. Achieving this balance requires combining pharmacological treatments with adequate protein intake and consistent strength training, ensuring that reduced food intake does not inadvertently lead to nutritional deficiencies.